Pharsight

Pliaglis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751305 TARO PHARMS Solid-forming topical formulations for pain control
Jan, 2031

(7 years from now)

US10350180 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

US10603293 TARO PHARMS Solid-forming local anesthetic formulations for pain control
Jan, 2031

(7 years from now)

Pliaglis is owned by Taro Pharms.

Pliaglis contains Lidocaine; Tetracaine.

Pliaglis has a total of 3 drug patents out of which 0 drug patents have expired.

Pliaglis was authorised for market use on 29 June, 2006.

Pliaglis is available in cream;topical dosage forms.

The generics of Pliaglis are possible to be released after 14 January, 2031.

Drugs and Companies using LIDOCAINE; TETRACAINE ingredient

Market Authorisation Date: 29 June, 2006

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

PLIAGLIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic